Biotech companies lead a weak week in IPOs. So far this year, 127 companies have come public, and the average first-day pop has been about 16%. In the past two weeks, 8 of...read more
Zynerba Pharmaceuticals, a preclinical biotech developing transdermal cannabinoid-based therapies, raised $42 million by offering 3 million shares at $14, the midpoint of the $13-$15 range. Perceptive Advisors, a biotech-focused hedge fund, has indicated an...read more
Zynerba Pharmaceuticals, a preclinical biotech developing cannabinoid-based therapies for osteoarthritis and epilepsy, announced terms for its IPO on Thursday. The Devon, PA-based company plans to raise $42 million by offering 3.0 million shares at a price...read more
US IPO Weekly Recap: A bad week besides biotech
Biotech companies lead a weak week in IPOs. So far this year, 127 companies have come public, and the average first-day pop has been about 16%. In the past two weeks, 8 of...read more
Pot patch company Zynerba prices IPO at $14, midpoint of the range
Zynerba Pharmaceuticals, a preclinical biotech developing transdermal cannabinoid-based therapies, raised $42 million by offering 3 million shares at $14, the midpoint of the $13-$15 range. Perceptive Advisors, a biotech-focused hedge fund, has indicated an...read more
Week ahead: 10 IPOs set to price during the week of August 3
August 2015 kicks off with ten IPOs on the calendar for this week - more IPOs than all of August 2014 - after a ...read more
Will it trade high? Cannabis biotech Zynerba Pharmaceuticals sets terms for $42 million IPO
Zynerba Pharmaceuticals, a preclinical biotech developing cannabinoid-based therapies for osteoarthritis and epilepsy, announced terms for its IPO on Thursday. The Devon, PA-based company plans to raise $42 million by offering 3.0 million shares at a price...read more